Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, Leavell MD, Tai A, Main A, Eng D, Polichuk DR, Teoh KH, Reed DW, Treynor T, Lenihan J, Fleck M, Bajad S, Dang G, Dengrove D, Diola D, Dorin G, Ellens KW, Fickes S, Galazzo J, Gaucher SP, Geistlinger T, Henry R, Hepp M, Horning T, Iqbal T, Jiang H, Kizer L, Lieu B, Melis D, Moss N, Regentin R, Secrest S, Tsuruta H, Vazquez R, Westblade LF, Xu L, Yu M, Zhang Y, Zhao L, Lievense J, Covello PS, Keasling JD, Reiling, K
The obvious question: what happens when you combine them
3.Clemmons DR
Why Brand-Name Cant Match Price Structural Barriers: Public Company Obligations: Must maximize shareholder return Quarterly earnings pressure Executive compensation tied to profits Cant dramatically reduce price without stock impact Sunk Costs: Billions invested in development Need to recoup investment Justify to shareholders and board Complex Distribution System: PBMs demand rebates Wholesalers take cut Pharmacy margins Cant easily change system Market Dynamics: Limited competition (patent protection) Can charge premium prices Demand exceeds supply No pressure to reduce Eli Lilly unlikely to reduce tirzepatide prices significantly while patents protected
Burping in GERD patients often brings stomach acid into the esophagus, causing heartburn and potentially damaging esophageal tissue